Clinical Genetic Test
offered by
GTR Test Accession:
Help
GTR000592394.4
CAP
Last updated in GTR:
2024-06-25
View version history
GTR000592394.4,
last updated:
2024-06-25
GTR000592394.3,
last updated:
2023-06-16
GTR000592394.2,
last updated:
2022-07-12
GTR000592394.1,
registered in GTR:
2021-01-26
Last annual review date for the lab: 2024-06-28
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Predictive;
Risk Assessment; ...
Conditions (35):
Help
Familial colorectal cancer;
BAP1-related tumor predisposition syndrome;
Birt-Hogg-Dube syndrome
more...
Genes (66):
Help
Methods (2):
Help
Molecular Genetics - Deletion/duplication analysis: Next-Generation (NGS)/Massively parallel sequencing (MPS); ...
Target population: Help
Not provided
Clinical validity:
Help
Not provided
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Specimen Source:
Help
- Buccal swab
- Cord blood
- Fibroblasts
- Fresh tissue
- Peripheral (whole) blood
- Saliva
Who can order: Help
- Health Care Provider
Test Order Code:
Help
38600
View other test codes
View other test codes
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
Informed consent required:
Help
Based on applicable state law
Pre-test genetic counseling required:
Help
No
Post-test genetic counseling required:
Help
No
Recommended fields not provided:
Lab contact for this test,
Test strategy,
Test development
Conditions
Help
Total conditions: 35
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 66
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument *
Deletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Predictive;
Risk Assessment;
Screening
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
The laboratory follows ACMG variant classification protocols
The laboratory follows ACMG variant classification protocols
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
Yes. Quest Diagnostic’s Family Insight Program allows for segregation analysis, or determining whether the VUS is tracking with the disease in the family. By gathering clinical and family history information on your patient, we are able to identify appropriate family members to offer testing for the VUS identified in your patient. … View more
Yes. Quest Diagnostic’s Family Insight Program allows for segregation analysis, or determining whether the VUS is tracking with the disease in the family. By gathering clinical and family history information on your patient, we are able to identify appropriate family members to offer testing for the VUS identified in your patient. … View more
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes. Inquiry by the ordering provider regarding potential changes to the classification of the variant is strongly recommended prior to making any clinical decision. If a variant is reclassified and this has clinical implications, Quest Diagnostics will endeavor to contact the ordering provider. For questions regarding variant classification updates, please call … View more
Yes. Inquiry by the ordering provider regarding potential changes to the classification of the variant is strongly recommended prior to making any clinical decision. If a variant is reclassified and this has clinical implications, Quest Diagnostics will endeavor to contact the ordering provider. For questions regarding variant classification updates, please call … View more
Recommended fields not provided:
Clinical validity,
Clinical utility,
Target population,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Test Procedure:
Help
Gene dosage is assessed by bioinformatic analysis of sequencing reads and confirmed as necessary by a custom targeted microarray
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
>99.9% specificity; >99.9% sensitivity
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
VUS:
Laboratory's policy on reporting novel variations
Help
Novel variations are reported
Novel variations are reported
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Not provided
Additional Information
Reviews:
Suggested reading:
Clinical resources:
Practice guidelines:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.